CAPR · Capricor Therapeutics, Inc.
$7.00
-6.14% last session
End-of-day data · updated 2026-07-29
Market cap
$0B
Enterprise value
$0B
Trailing P/E
—
Forward P/E
-9.7
Dividend yield
—
Beta
0.42
Avg volume
2M
Employees
0K
2D change
-6.14%
5D change
-66.65%
10D change
-66.20%
30D change
-72.39%
60D change
-78.07%
MTD change
-71.52%
YTD change
-77.23%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CAPR
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-13
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-13 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
| 2026-03-13 | B. Riley Securities | Maintains | Buy | $50.00 → $63.00 |
| 2026-03-13 | Piper Sandler | Reiterates | Overweight | $45.00 → $58.00 |
| 2026-03-13 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
| 2026-03-10 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
| 2025-12-15 | B. Riley Securities | Reiterates | Buy | $21.00 → $50.00 |
| 2025-12-10 | Piper Sandler | Reiterates | Overweight | $20.00 → $45.00 |
| 2025-12-08 | Oppenheimer | Maintains | Outperform | $22.00 → $54.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 13 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 73.2% below the 50-day MA ($24.52).
- Price vs 200-day MA: Trading 71.8% below the 200-day MA ($23.32).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-1.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($4.60) and high ($35.34).
CAPR Price Chart
Loading chart for CAPR…
Fundamentals
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.